JP2019524883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524883A5 JP2019524883A5 JP2019529309A JP2019529309A JP2019524883A5 JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5 JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cyclyl
- heterocyclyl
- group
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000004122 cyclic group Chemical group 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrugs Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 125000005418 aryl aryl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108091008101 FGF receptors Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 102000017175 fibroblast growth factor-activated receptor activity proteins Human genes 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004432 carbon atoms Chemical group C* 0.000 claims 3
- 125000005842 heteroatoms Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- -1 --CN Inorganic materials 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610647295.0A CN107698593A (zh) | 2016-08-09 | 2016-08-09 | 作为fgfr抑制剂的杂环化合物 |
| CN201610647295.0 | 2016-08-09 | ||
| PCT/CN2017/094620 WO2018028438A1 (zh) | 2016-08-09 | 2017-07-27 | 作为fgfr抑制剂的杂环化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524883A JP2019524883A (ja) | 2019-09-05 |
| JP2019524883A5 true JP2019524883A5 (US07794700-20100914-C00125.png) | 2020-07-16 |
| JP6959663B2 JP6959663B2 (ja) | 2021-11-02 |
Family
ID=61162708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529309A Active JP6959663B2 (ja) | 2016-08-09 | 2017-07-27 | Ｆｇｆｒ阻害剤としての複素環化合物 |
Country Status (7)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018266705B2 (en) | 2017-05-08 | 2023-05-04 | Gritstone Bio, Inc. | Alphavirus neoantigen vectors |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020236524A1 (en) * | 2019-05-17 | 2020-11-26 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021285974A1 (en) * | 2020-06-05 | 2023-01-19 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
| CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
| JP2024503661A (ja) * | 2021-01-12 | 2024-01-26 | ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド | （ｓ）－１－（１－アクリロイルピロリジン－３－イル）－３－（（３，５－ジメトキシフェニル）エチニル）－５－（メチルアミノ）－１ｈ－ピラゾール－４－カルボキサミドの製造方法 |
| CN114853739B (zh) * | 2021-02-03 | 2023-09-22 | 药雅科技(上海)有限公司 | 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途 |
| CN115043832B (zh) * | 2021-03-08 | 2023-08-22 | 药雅科技(上海)有限公司 | 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途 |
| WO2024083111A1 (zh) * | 2022-10-18 | 2024-04-25 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| PL2657233T3 (pl) | 2012-01-19 | 2015-01-30 | Taiho Pharmaceutical Co Ltd | 3,5-dipodstawiony związek alkinylobenzenowy i jego sól |
| EP2970206A1 (en) * | 2013-03-13 | 2016-01-20 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| DK3023100T3 (da) * | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| WO2015008844A1 (ja) * | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| CN104341425B (zh) * | 2013-08-08 | 2018-11-02 | 上海医药集团股份有限公司 | 氘代乙炔衍生物、其药物组合物及应用 |
| SG11201602070TA (en) * | 2013-09-30 | 2016-04-28 | Beijing Synercare Pharma Tech Co Ltd | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
| MX2017002206A (es) * | 2014-08-19 | 2018-01-23 | Shanghai Haihe Pharmaceutical Co Ltd | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos. |
-
2016
- 2016-08-09 CN CN201610647295.0A patent/CN107698593A/zh active Pending
-
2017
- 2017-07-27 CN CN201780045675.XA patent/CN109715626B/zh active Active
- 2017-07-27 EP EP17838568.8A patent/EP3498706A4/en not_active Withdrawn
- 2017-07-27 US US16/324,189 patent/US10752631B2/en active Active
- 2017-07-27 WO PCT/CN2017/094620 patent/WO2018028438A1/zh unknown
- 2017-07-27 CA CA3032921A patent/CA3032921A1/en active Pending
- 2017-07-27 KR KR1020197006637A patent/KR20190035870A/ko not_active Application Discontinuation
- 2017-07-27 JP JP2019529309A patent/JP6959663B2/ja active Active
